HSE have published their latest bulletins:
Upcoming GB active substance renewal submission deadlines: Apply for active substance renewal by the deadlines to keep products on the GB market
Under the GB BPR, active substance approvals will expire unless a renewal application is submitted at least 550 days before their expiry date.
The 550-day deadlines are coming up for the following active substance/product type combinations under GB BPR:
- 4-bromo-2-(4-chlorophenyl)-1-ethoxymethyl-5-trifluoromethylpyrrole-3-carbonitrile (Chlorfenapyr) (CAS 122453-73-0 EC n/a) in product type 08 (deadline: 28 October 2023)
- 3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate (Permethrin) (CAS 52645-53-1 EC 258-067-9) in product types 08 and 18 (deadline: 27 October 2024)
Any person, company or taskforce/consortium can support an active substance/product type combination for renewal – it doesn’t have to be the original supporter. Check the GB Article 95 List to see who the original supporters were.
If any of these active substance/product type combinations are important to you, consider contacting your supplier to let them know. If a renewal application is not submitted for the above active substance/product type combinations under GB BPR, the approvals will expire. This means the active substances can no longer be used in biocidal products of the relevant product types in GB.
Upcoming GB active substance expiry dates: Biocidal products must be phased off the GB market
The active substance/product type combination listed below is due to expire under the GB BPR on the following date:
- 2,2-dimethyl-1,3- benzodioxol-4-yl methylcarbamate (Bendiocarb) (CAS 22781-23-3 EC 245-216-8) in product type 18 (deadline: 31 January 2024)
Once the approval expires, the active substance can no longer be used in biocidal products of the relevant product types in GB. If you hold an affected GB BPR product authorisation or Control of Pesticides Regulations (COPR) product approval, we will contact you about cancelling or revoking your authorisation or approval. You will have an opportunity to submit comments or additional information and we will take account of these when finalising our decision.
If you are aware of any disproportionate negative effects that are likely to arise from the expiry of any of the active substance/product type combinations listed above, please contact us.